Αντιβιοτικά

ATC CODE V03AF02

DEXRAZOXANE

Δεξραζοξάνη

An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit formation of a …

Chemical structure of DEXRAZOXANE

Φαρμακολογικό Προφίλ

Πηγή: DrugBank

Περιγραφή & Ένδειξη

An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit formation of a toxic iron-anthracycline complex. [PubChem] The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy.

Κύρια Ένδειξη

For reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin hydrochloride dose of 300 mg/m^2 and would benefit from continued doxorubicin therapy. Also approved for the treatment of extravasation from intravenous anthracyclines.

Χρόνος Ημιζωής

2.5h

2.5 hours

Σύνδεση Πρωτεϊνών

Very low (< 2%)

Δείτε αναλυτικό φαρμακολογικό προφίλ.

+ Περισσότερες Φαρμακολογικές Πληροφορίες

Μηχανισμός Δράσης

The mechanism by which dexrazoxane exerts its cardioprotective activity is not fully understood. Dexrazoxane is a cyclic derivative of EDTA that …

Οδός Αποβολής

Urinary excretion plays an important role in the elimination of dexrazoxane. Forty-two percent of the 500 mg/m2 dose of dexrazoxane was excreted in …

Όγκος Κατανομής

* 9 to 22.6 L/m^2

Κατηγορίες ATC

Βρείτε τη δραστική μέσα από τις αντίστοιχες κατηγορίες ATC level 5.

Διαθέσιμα Σκευάσματα

Εγκεκριμένα φαρμακευτικά σκευάσματα που περιέχουν DEXRAZOXANE.

Φόρτωση σκευασμάτων...